Summary of COVID-19 mefenamic acid studies

1. Guzman‑Esquivel et al., Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial

36 patient mefenamic acid early treatment RCT: 94% improved recovery (p=0.03).
RCT 36 COVID-19 outpatients showing reduced time to an "acceptable symptom state" with mefenamic acid treatment, however the effect was driven by pain-related symptoms and is likely, at least in part, due to mefenamic acid’s analgesic action.
Jan 2022, Int. J. Molecular Medicine, http://www.spandidos-publications.com/10.3892/ijmm.2022.5084, https://c19p.org/guzmanesquivel